Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancy 1MDS 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Peripheral Blood Stem Cell Transplantation 49Mycophenolic Acid 39Busulfan 38Tacrolimus 37Cyclosporine 33Antilymphocyte Serum 33Whole-Body Irradiation 32Filgrastim 28Methotrexate 27Radiotherapy 20Melphalan 18Cytarabine 17fludarabine 16Etoposide 16Methylprednisolone 14ruxolitinib 11sargramostim 9Flow Cytometry 9Cyclosporins 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 9thymoglobulin 8Sirolimus 8Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 8Azacitidine 8merphos 7Decitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myeloproliferative Disorders × eprenetapopt × Clear all
NCT03072043 2022-01-24

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
55 enrolled 15 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡